A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee

T. Pincus*, G. G. Koch, T. Sokka, J. Lefkowith, F. Wolfe, J. M. Jordan, G. Luta, L. F. Callahan, X. Wang, T. Schwartz, S. B. Abramson, J. R. Caldwell, R. A. Harrell, J. M. Kremer, R. L. Lautzenheiser, J. A. Markenson, Thomas J Schnitzer, A. Weaver, P. Cummins, A. WilsonS. Morant, J. Fort

*Corresponding author for this work

Research output: Contribution to journalArticle

202 Scopus citations

Abstract

Objective. To perform a randomized, double-blind, crossover clinical trial of diclofenac + misoprostol versus acetaminophen in ambulatory patients with osteoarthritis of the hip or knee. Methods. Patients in 12 ambulatory care settings were eligible if they were age >40 years and if they had Kellgren/Lawrence radiographic grade 2-4 osteoarthritis of the knee or hip and a score of ≥30mm on a 100-mm visual analog pain scale. Patients were randomized to one of two groups, 75 mg diclofenac + 200 μg misoprostol twice daily or 1,000 mg acetaminophen 4 times daily (each for 6 weeks), and were then crossed over to the other treatment for 6 weeks. A placebo was included in each treatment regimen to enable double blinding. The primary outcome measures were the Western Ontario and McMaster Universities Osteoarthritis Index and the visual analog pain scale of the Multidimensional Health Assessment Questionnaire. Safety was assessed using a standard form to review adverse events. Results. We enrolled 227 patients, of whom 218 provided data for the first treatment period and 181 provided data for both treatment periods. Significantly higher levels of improvement in the primary outcomes were seen for diclofenac + misoprostol than for acetaminophen (P < 0.001). Adverse events were more common when patients took diclofenac + misoprostol (P = 0.046). Diclofenac + misoprostol was rated as "better" or "much better" by 57% of the 174 patients who provided such ratings for both treatment periods, while acetaminophen was rated as "better" or "much better" by 20% of these patients, and 22% reported no difference (P < 0.001). Differences favoring diclofenac + misoprostol over acetaminophen were greater in patients with more severe osteoarthritis according to baseline pain scores, radiographs, or number of involved joints. Conclusion. Patients with osteoarthritis of the hip or knee had significantly greater improvements in pain scores over 6 weeks with diclofenac + misoprostol than with acetaminophen, although patients with mild osteoarthritis had similar improvements with both drugs. Acetaminophen was associated with fewer adverse events.

Original languageEnglish (US)
Pages (from-to)1587-1598
Number of pages12
JournalArthritis and Rheumatism
Volume44
Issue number7
DOIs
StatePublished - Jul 24 2001

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee'. Together they form a unique fingerprint.

  • Cite this

    Pincus, T., Koch, G. G., Sokka, T., Lefkowith, J., Wolfe, F., Jordan, J. M., Luta, G., Callahan, L. F., Wang, X., Schwartz, T., Abramson, S. B., Caldwell, J. R., Harrell, R. A., Kremer, J. M., Lautzenheiser, R. L., Markenson, J. A., Schnitzer, T. J., Weaver, A., Cummins, P., ... Fort, J. (2001). A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis and Rheumatism, 44(7), 1587-1598. https://doi.org/10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X